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Abstract Supra-physiological levels of vitamin D induce
skeletal muscle atrophy, which may be particularly detri-
mental in already sarcopaenic elderly. Neither the cause
nor whether the atrophy is fibre type specific are known. To
obtain supraphysiological levels of circulating vitamin D
(1,25(OH)2D3) 27.5-month-old female Fischer344 9 Brown
Norway F1 rats were orally treated for 6 weeks with
vehicle or the vitamin D analogue alfacalcidol. Alfacalci-
dol treatment induced a 22% decrease in body mass and
17% muscle atrophy. Fibre atrophy was restricted to type
IIb fibres in the low-oxidative part of the gastrocnemius
medialis only (-22%; P \ 0.05). There was a concomitant
1.6-fold increase in mRNA expression of the ubiquitin
ligase MuRF-1 (P \ 0.001), whereas those of insulin-like
growth factor 1 and myostatin were not affected. Circu-
lating IL-6 was unaltered, but leptin and adiponectin were
decreased (-39%) and increased (64%), respectively. The
treated rats also exhibited a reduced food intake. In con-
clusion, supraphysiological levels of circulating
1,25(OH)2D3 cause preferential atrophy of type IIb fibres,
which is associated with an increased expression of MuRF-
1 without evidence of systemic inflammation. The atrophy
and loss of body mass in the presence of supra-physio-
logical levels of vitamin D are primarily due to a reduced
food intake.
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Introduction
Elderly vitamin D-deficient people are at a higher risk of
sarcopaenia than those with normal levels of vitamin D [1].
Also, in young people, a positive relationship between
vitamin D status and muscle performance has been repor-
ted [2, 3]. Given these observations, it is no surprise that
8–12 weeks vitamin D plus calcium supplementation in
institutionalized vitamin D-deficient elderly people
improved musculoskeletal function by 4–11% [4] and body
sway by 9% in ambulatory elderly women [5]. These
benefits may contribute to the 22% lower risk of falling
after long-term supplementation of vitamin D in vitamin
D-deficient people [6].
Vitamin D may exert these beneficial effects via its impact
on Ca2? homeostasis, and by proliferation and differentia-
tion of myoblasts [7]. The latter two effects are probably
mediated via the interaction of vitamin D with the vitamin D
receptor (VDR) as VDR knock-out mice suffer from
abnormal muscle development and deregulated expression
of myogenic regulatory factors [8]. The impact of vitamin D
on muscle is also reflected by the increase in muscle mass and
decreased rate of myofibrillar protein degradation after
vitamin D administration to deficient rats [9]. Also, in
humans, vitamin D administration in vitamin D-deficient
people induces increases in muscle size and strength, and an
increased proportion and size of type II fibres [10].
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CYP27B1 is a hydroxylase that catalyses the hydrox-
ylation of 25D to the active form of vitamin D (1,25D).
Although the hydroxylation of 25D occurs mainly in the
kidney, 1,25D is also produced extra-renally [11], probably
including muscle. The expression of the hydroxylase
CYP27B1 in the muscle may serve to dampen the impact
of fluctuations in circulating 1,25D levels on the intracel-
lular 1,25D concentration that could otherwise cause
dysregulation of gene expression and Ca2? homeostasis.
It has been shown in a human liver cell line that max-
imal VDR activity occurs at concentrations of 1,25D far
above physiological circulating levels [12]. One might thus
speculate that supraphysiological 1,25D serum levels
would accentuate the hypertrophic effects of vitamin D
described above. Yet, we have shown that increased 1,25D
serum levels in rats after alfacalcidol supplementation, a
vitamin D analogue which is converted into 1,25D, were
accompanied by a reduction in body mass, muscle atrophy
and muscle weakness [13], rather than hypertrophy and
improvements in muscle strength. Elucidating the cause of
this muscle atrophy would enhance our understanding of
the role of vitamin D in the regulation of skeletal muscle
size and its contractile characteristics.
Previously, we have observed that the loss of body and
muscle mass during alfacalcidol treatment was associated
with a reduced food intake [13]. Reductions in food intake
may be caused by altered sensations of satiety. The hor-
mone leptin plays an important role in the regulation of
food intake and feelings of satiety and is positively related
to the amount of body fat [14]. Adiponectin, on the other
hand, plays a role in the regulation of metabolism and is
inversely related to the amount of body fat [15, 16]. Ele-
vated levels of interleukin 6 (IL-6) may also reduce food
intake [17] and contribute to muscle wasting via abolishing
the normally anabolic effect of insulin-like growth factor 1
(IGF-1) [18]. The muscle breakdown may be realised by an
increased expression of the muscle specific ubiquitin liga-
ses, MAFbx and MuRF-1, that play an important role in
protein breakdown, as observed during undernutrition [19–
22] and systemic inflammation [23]. It is thus possible that
undernutrition and inflammation may induce the expres-
sion of the muscle specific E3 ubiquitin ligases and thereby
contribute to the loss of body and muscle mass during
alfacalcidol supplementation.
The aim of this study was to determine how alfacalcidol
supplementation, which was initially thought to counteract
sarcopaenia, actually induced muscle wasting. We
hypothesised that alfacalcidol supplementation causes (1)
the previously observed malnutrition [13] due to increased
leptin and decreased adiponectin levels, (2) systemic
inflammation contributing to the loss of body and muscle
mass, (3) muscle atrophy via a decrease in the expression
of anabolic and an increase in the expression of catabolic
factors, and (4) a reduced expression of the VDR and
CYP27B1 in the muscle which would attenuate the
increase in the level of 1,25D within the muscle fibres.
Materials and methods
Animals
Female Fischer344 9 Brown Norway F1 rats were obtained
from Harlan (USA) (n = 16). This strain of rats is rec-
ommended by the National Institute of Ageing as the strain
of choice for the study of ageing as it suffers less than other
strains from co-morbidities [24]. Rats were housed one to a
cage at a 12:12 h light dark cycle with food and standard
laboratory chow provided ad libitum. The rats were 7 and
27.5 months old at the end of the experiment. The 27.5-
month-old rats were randomly divided in alfacalcidol- or
vehicle-treated groups (Table 1). Rats were orally admin-
istered vehicle or alfacalcidol (0.1 lg kg-1) (Chugai
Pharmaceutical, Japan), 5 days a week during 6 weeks.
This dose has been shown to inhibit bone resorption and
enhance bone formation in ovariectomized rats treated for
5 weeks [25]. The 7-month-old rats did not receive any
treatment. Food and water consumption were monitored in
the 6-week-treatment groups. All experiments were
approved by the local ethics committee of the VU Uni-
versity Amsterdam and conform to the Dutch Research
Council’s guide for care and use of laboratory animals.
Rats were anaesthetised by an initial dose of urethane
(0.75 g kg-1 i.p). After 10 min, an additional dose of
0.75 g kg-1 urethane was given. If the rats still responded
to nociceptive stimuli, supplementary injections of
0.63 g kg-1 were applied during the experiment. Con-
tractile properties of the gastrocnemius medialis muscle
(Gm) were determined as described previously [13].
Briefly, the sciatic nerve was cut and contractions induced
by supramaximal electrical stimulation of the nerve. Sub-
sequently, the muscle was set at optimal length (Lo),
Table 1 Number of animals in each group, with treatment and age of
the rats at the end of the experiment
Group No. of
animals
Treatment Age
(months)
CA 9 None 7
A6WO 9 6 weeks alfacalcidol (0.1 lg (in
1 ml) kg-1 BM)
27.5
V6WO 9 6 weeks vehicle (1 ml kg-1 BM) 27.5
Data from [13]
CA control adult, A6WO (alfacalcidol for 6 weeks, old), old rats
treated with alfacalcidol for 6 weeks, V6WO (vehicle for 6 weeks,
old), old rats treated with vehicle for 6 weeks, BM body mass
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defined as the length at which the active twitch force was
maximal. Then, Lo was fine-adjusted with several tetanic
contractions (150 Hz, 150 ms). After completion of the
contractile measurements (data presented elsewhere [13]),
the Gm of the right leg was excised, weighed, stretched to
Lo on cork and frozen in liquid nitrogen with vigorous
shaking.
Cryosectioning
Muscles were frozen in liquid nitrogen and stored at
-80C until use. Cross-sections (10 lm) of the muscles
were cut from 1/3 to 1/2 of its length distally from origin
using a cryostat at -20C. Sections were collected on
Vectabond (Vector Laboratories, Burlingame, CA, USA)-
coated slides air- dried for at least 10 min at room tem-
perature and stored at -80C until further use.
Fibre type composition
Sections were stained for myosin ATPase to determine the
fibre type composition as described previously [26]. In
short, two complementary techniques were used: (1)
staining following 10 min preincubation at pH 4.7 at room
temperature (acid (ac)-ATPase [27]); (2) staining following
consecutive pre-treatments of (a) 5 min fixation with 5%
paraformaldehyde at 4C and pH 7.6 and (b) 15 min pre-
incubation at pH 10.55 at room temperature [28]. The
muscle fibres were classified by eye into four types
according to their staining properties for mATPase [26]. In
the same fibres, we determined the cross-sectional area
(CSA).
Total RNA isolation
Total RNA was extracted from the low oxidative, distal
part of the Gm using the RiboPure kit (Applied Biosys-
tems, Foster City, CA, USA) according to the instructions
of the manufacturer. RNA concentrations were determined
in duplet by spectroscopy (ND-1000 spectrophotometer;
Nanodrop Technologies, Wilmington, DE, USA). RNA
purity was verified by the 260:280 ratio (range 1.90–2.10,
mean 2.04). The RNA concentration was presented as lg
RNA per mg muscle mass.
Reverse transcription (RT)
Five hundred nanograms of total RNA per muscle were
reverse transcribed using the high capacity RNA-to-
cDNA kit (Applied Biosystems) containing random
primers in a 20-ll total reaction volume. Tubes were
heated at 25C for 5 min, followed by 42C for 30 min.
Finally, the tubes were heated to 85C for 5 min to stop
the reaction, and stored at -20C until used in the qPCR
reaction.
qPCR
Quantitative PCR was performed to study the expression of
18S RNA and mRNAs of a-skeletal actin, insulin-like
growth factor-I Ea (IGF-I Ea), muscle ring finger-1 (MuRF-
1), muscle atrophy F-box (MAFbx), myostatin, c-myc,
vitamin D receptor (VDR) and CYP27B1. The sequences
for the primers (Invitrogen, The Netherlands) are shown in
Table 2. For each target, RT and PCR reactions were car-
ried out under identical conditions by using the same
reagent premix for all samples. Five microlitres of each RT
reaction were used for the PCR amplification. cDNA dilu-
tions were set so that both the target mRNA and 18S product
yields were in the linear range of the semi-log plot where
the yield is expressed as a function of the number of cycles.
Amplifications were carried out in duplet in a StepOne real-
time PCR machine (Applied Biosystems, Carlsbad, CA,
USA) with an initial activation/denaturing step of 23 s at
95C followed by an annealing step of 30 s at 60C. The
range of cycle threshold values was 15–30. Specificity was
confirmed by melting curve analysis after amplification.
18S RNA and mRNA data were normalized to total RNA
per sample as well as to the mass of tissue used to extract the
RNA used for cDNA synthesis. Differences in mRNA for
each primer are shown relative to 18S RNA.
Serum cytokine levels
Blood was collected from the vena cava after the con-
tractile properties of the Gm had been determined. Circu-
lating Leptin and adiponectin (Invitrogen, Camarillo, CA,
USA) and IL-6 (Bender MedSystems, Vienna, Austria)
levels were determined in serum with ELISAs according to
the instruction of the manufacturer. To minimise bias
related to the circadian changes in, e.g., leptin concentra-
tions [29, 30], all rats were kept in similar light–dark
conditions and blood was collected at the same time of day.
Statistics
SPSS v.16.0 (SPSS, Chicago, IL, USA) was used for
statistical analysis. One-way ANOVA was performed to
assess whether there were any significant differences
between (1) the alfacalcidol and the age-matched vehicle
group, (2) the alfacalcidol and the control adult group, and
(3) the old vehicle and control adult group. ANOVA was
also used to assess potential differential effects of alfacal-
cidol on the different fibre types in the low and high oxi-
dative region. Differences were considered significant at
P \ 0.05. Data are presented as mean ± SEM.
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Results
Body and muscle mass
Table 3 shows the mean body and muscle mass as well as
the 1,25D serum concentrations. The old animals were
20% heavier than the adult animals (P \ 0.01). Vehicle
treatment did not significantly affect body mass. Six weeks
treatment with alfacalcidol, however, caused a 22% loss of
body mass in the old rats (P = 0.001).
The serum concentration of 1,25D in the V6WO was
comparable to those of the CA group, indicating that age
and vehicle had no effect on the 1,25D serum concentra-
tion. After 6 weeks of treatment with alfacalcidol, 1,25D
serum levels were fivefold increased to 234 pmol l-1
(P \ 0.01) (Table 3).
Ageing did not significantly affect the mass of the gas-
trocnemius (Gm) (Table 3), soleus, plantaris, extensor
digitorum longus and tibialis anterior muscles (data not
shown). Six weeks of alfacalcidol treatment caused a 17%
reduction in Gm mass (P \ 0.001). Plantaris muscle mass
was reduced in the same order of magnitude (P \ 0.05),
but the mass of the other muscles was not significantly
affected by alfacalcidol. The Gm mass:body mass ratio was
lower in the old than in the adult rats (P \ 0.001). Treat-
ment with alfacalcidol did not change this ratio, indicating
that the decrease in body mass was not only due to a
decrease in muscle mass, but also to a proportionally
similar decrease in the mass of other tissues.
Fibre type distribution and cross-sectional area
The high oxidative part contained approximately 25% type
I, 20% type IIa and 55% type IIb/x fibres (Fig. 1a), and the
low oxidative part 10% type IIa, 50% type IIx, 40% IIb
fibres with almost no type I fibres (Fig. 1c). The fibre type
distributions were not significantly affected by age and/or
alfacalcidol treatment.
In all groups, the CSA of the different fibre types were
similar in the high and low oxidative part of the Gm
(Fig. 1b, d). For all fibres pooled, the CSA in high oxida-
tive part of the old vehicle treated Gm was 22% larger than
that of the control adult rats (P = 0.018) (Fig. 2b). This
was primarily due to the increased size of type IIa fibres in
Table 2 Sequence of the specific primers used in the quantitative PCR analyses
Target mRNA PCR primer sequence 5’ ? 3’ Tm Efficiency R
2 Acession number
18S RNA Forward: CGAACGTCTGCCCTATCAACTT
Reverse: ACCCGTGGTCACCATGGTA
77.27 102.0 0.998 EU139318.1
a-skeletal actin Forward: CGACATCGACATCAGGAAGGA
Reverse: GGTAGTGCCCCCTGACATGA
76.37 94.5 1 NM_019212.2
IGF-1 Ea Forward: AAGCCTACAAAGTCAGCTCG
Reverse: TCAAGTGTACTTCCTTCTGAGTC
78.76 91.3 0.997 NM_178866.4
MAFbx Forward: TGAAGACCGGCTACTGTGGAA
Reverse: CGGATCTGCCGCTCTGA
75.46 95.5 0.999 NM_133521.1
MuRF-1 Forward: TGCCCCCTTACAAAGCATCTT
Reverse: CAGCATGGAGATGCAATTGC
73.38 98.17 0.998 NM_080903.1
Myostatin Forward: GGTCCCGGAGAGACTTTGG
Reverse: CGACAGCACCGCGATTC
77.71 96.2 0.999 NM_019151.1
c-myc Forward: CACAACGTCTTGGAACGTCAGA
Reverse: GCGCAGGGCAAAAAAGC
75.34 91.3 0.998 NM_012603.2
VDR Forward: CACCCTTGGGCTCTACTCAC
Reverse: CTGTTGCCTCCATCCCTGAA
74.74 112.7 0.98 NM_017058.1
CYP27B1 Forward: CGGGAAAAGGTGTCTGTCCA
Reverse: GTGTCCACTCCAGTAG
75.48 107.2 0.966 NM_053763.1
IGF-1 insulin-like growth factor-1 Ea, MAFbx muscle atrophy F-box, MuRF-1 muscle RING finger-1, VDR vitamin D receptor
Table 3 Body mass, gastrocnemius muscle (Gm) mass and 1,25D
serum levels
Group Body
mass (g)
Gm mass
(mg)
[1,25D]
(pmol l-1)
CA 221 (5) 669 (16) 46.6 (6.88)
A6WO 224 (6)* 515 (12)* 233.8 (60.0)**
V6WO 276 (12) 622 (18) 57.1 (11.5)
Data are represented as mean ± SEM; Data from [13]
* Significantly different from V6WO, ** significantly different from
CA and V6WO (P \ 0.05). (ANOVA, Bonferroni posthoc)
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this region of the old vehicle group than the control adult
group (Fig. 1b; P = 0.012). There was no significant dif-
ference in overall CSA in the high oxidative part of the Gm
between the old vehicle and alfacalcidol groups (Fig. 2a).
In the low oxidative region of the Gm, however, the CSA
of the old alfacalcidol-treated group was 16% smaller
(P = 0.029) than that of the old vehicle-treated rats
(Fig. 2b), which was primarily due to a decrease of the
CSA of type IIb fibres (P = 0.029) (Fig. 1d).
Effects of age and alfacalcidol on mRNA expression
To clarify how alfacalcidol induces atrophy of the fibres in
the low oxidative part of the Gm, mRNA levels of genes
involved in the regulation of protein synthesis and degra-
dation were determined. As the atrophy was apparent in the
distal, low oxidative, part of the Gm, qPCR analyses were
performed on this part only. Total RNA per milligram
muscle was similar in the alfacalcidol, vehicle and adult
control groups (Fig. 3a). mRNAs were normalized to the
18S ribosomal RNA expression. Figure 3b shows that the
expression levels of the structural protein a-skeletal actin
and the ubiquitin ligase MAFbx were similar in all groups.
In contrast, the ubiquitin ligase MuRF-1 was upregulated in
the old vehicle group compared to the control adult group
(P \ 0.05) and was further elevated after alfacalcidol
treatment (P \ 0.001) (Fig. 3b).
The mRNA level of the autocrine growth factor myosta-
tin, involved in regulating protein synthesis and degradation
and satellite cell proliferation, was reduced with ageing
(P = 0.002). However, myostatin mRNA expression was
not significantly affected by alfacalcidol. IGF-1 Ea and
c-myc mRNA expression levels as well as that of the vitamin
D related markers, VDR and CYP27B1, were similar in all
groups (Fig. 3c, d).
Circulating factors
The inflammatory marker IL-6, which is associated with
sarcopaenia and muscle wasting [18], was elevated in the
old rats (P \ 0.05), but was not significantly elevated
further after treatment with alfacalcidol. The adiponectin
serum concentration was 64% higher in the alfacalcidol
group compared to that of the vehicle group (P = 0.004),
but was not significantly different from that of the control
adult group. The leptin serum concentration was decreased
Fig. 1 Fibre type distribution
(a, c) and cross-sectional area
(CSA) (b, d) of the fibre types in
the high oxidative (a, b) and
low oxidative (b, d) parts of the
gastrocnemius medialis muscle.
Fibre type composition (left)
and CSA of the different fibre
types (right). There were no
significant changes in fibre type
composition during ageing or
alfacalcidol treatment. The CSA
of the type IIa fibres in the high
oxidative part of the old vehicle
group were larger than that of
the adult group. In the low
oxidative part, type IIb fibres of
the alfacalcidol-treated animals
were significantly smaller
compared to the age-matched
vehicle group. CA control adult,
A6WO (alfacalcidol for
6 weeks, old), old rats treated
with alfacalcidol for 6 weeks,
V6WO (vehicle for 6 weeks,
old), old rats treated with
vehicle for 6 weeks; #different
from CA (P = 0.018);
*different from V6WO
(P = 0.029); (repeated-
measures ANOVA, Bonferroni
posthoc); data are represented as
mean ± SEM
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Fig. 2 Combined cross-sectional area of different fibre types of the
high oxidative (a) and low oxidative (b) parts of the Gastrocnemius
medialis muscle. In the high oxidative part the CSA of the control
adult group was smaller than that of the old vehicle group. In the low
oxidative part the CSA of the alfacalcidol-treated animals was smaller
compared to the age-matched vehicle group. CA control adult, A6WO
(alfacalcidol for 6 weeks, old), old rats treated with alfacalcidol for
6 weeks, V6WO (vehicle for 6 weeks, old), old rats treated with
vehicle for 6 weeks; #different from CA (P = 0.012); *different from
V6WO (P = 0.030); (ANOVA, Bonferroni posthoc); data are repre-
sented as mean ± SEM
Fig. 3 Quantitative PCR of contractile protein, components of the
ubiquitin proteasome pathway, growth factors and vitamin D-asso-
ciated proteins of the low oxidative, distal part of the Gm. a Total
RNA per milligram muscle. No differences in total RNA concentra-
tion were observed between the groups indicating that it was allowed
to normalise the expression of the other factors for 18S RNA.
b Expression of the structural protein a-actin and the ubiquitin
proteasome pathway proteins MAFbx and MuRF-1. The expression of
MuRF-1 in the vehicle group was higher compared to the control
adult group. MuRF-1 expression was further increased in the
alfacalcidol treated group. c Expression of the growth factors
myostatin and IGF-1 Ea. Myostatin expression was lower in the
alfacalcidol and vehicle group than the control adult group. d c-myc,
vitamin D receptor (VDR) and CYP27B1 expression were not
different between groups. CA control adult, A6WO (alfacalcidol for
6 weeks, old), old rats treated with alfacalcidol for 6 weeks, V6WO
(vehicle for 6 weeks, old), old rats treated with vehicle for 6 weeks;
*different from CA at P \ 0.05; #different from CA and V6WO at
P \ 0.001 (ANOVA, Bonferroni posthoc); data are represented as
mean ± SEM
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in the alfacalcidol group compared to the age-matched
vehicle group (P = 0.034) (Fig. 4).
Discussion
As far as we know this is the first study that addresses
some of the potential mechanisms whereby supraphysio-
logical circulating levels of the active form of Vitamin D
affect skeletal muscle. The main observation of the
present study is that supraphysiological levels of circu-
lating active vitamin D in old rats induce muscle atrophy
that is proportional to the decline in body mass. The
concomitant increase in the expression of MuRF-1, sup-
erimposed on the age-related increase in MuRF-1 exp-
ression, is consistent with the hypothesis that MuRF-1 is
involved in muscle atrophy. The increased expression
of MuRF-1 in rats with supraphysiological levels of
circulating vitamin D was not associated with a rise in
circulating IL-6. A likely cause of the loss of body mass
and increased MuRF-1 expression is the reduced food
intake in the animals with supraphysiological levels of
circulating vitamin D [13]. Unexpectedly, the decreased
food intake was accompanied with reduced, rather than
increased, serum leptin levels. Despite elevated circulating
levels of 1,25D, the VDR and CYP27B1 mRNA expres-
sion levels remained unaltered during ageing and alfa-
calcidol treatment. This suggests that the main cause of
atrophy induced by elevated levels of circulating vitamin
D is a reduced food intake and not systemic inflammation
and/or altered satiety set-points.
Effects of ageing
Similar to previous observation in both human [31] and rat
muscles [32, 33], we observed that the specific tension
(maximum tetanic force per muscle per muscle mass or
cross-sectional area) was decreased in the muscles from the
old animals [13].
As we observed previously [34], the similar muscle
mass but larger fibre cross-sectional area in older Gm
suggests that the number of fibres was reduced during
ageing. This might be the result of an incomplete dener-
vation–reinnervation process leading to loss of fibres [35]
and compensatory hypertrophy of the remaining fibres.
Such a process might also explain why muscle mass was
not changed even though the (mRNA) expression of the
ubiquitin ligase MuRF-1 was elevated (similar as in aging
human vastus lateralis muscle [36]). A possible increase in
the protein degradation rate consequent to the increased
MuRF-1 expression [19, 37] may be attenuated by the
reduced expression of myostatin in the old rats, as myost-
atin enhances protein degradation and reduces protein
synthesis [38, 39]. Alternatively, the elevated MuRF-1
occurs primarily in the denervated fibres while the decrease
in myostatin occurs primarily in the fibres undergoing
compensatory hypertrophy. Other compensatory mecha-
nisms may also have prevented the development of atrophy
at this age, but neither c-myc, a transcription factor
involved in the regulation of rRNA expression [40], nor the
anabolic IGF-1 Ea mRNA [41] were elevated in the old rats
in our study.
Another explanation might be that the increased
mRNA levels of MuRF-1, the reduced levels of myost-
atin mRNA and unaltered IGF-I Ea mRNA levels toge-
ther with the elevated circulating levels of IL-6 in the old
animals indicates the beginning of sarcopaenia induced
by low grade systemic inflammation [42]. Also, in
humans, loss of muscle strength may occur without
muscle fibre atrophy, similar to the reduction in specific
tension in old rat muscles [43]. Overall, it thus appears
that our old rats showed age effects similar to those
observed at the onset of sarcopaenia in humans and
suggests that the rat can serve as a model to study the
mechanisms and type of atrophy caused by elevated
levels of vitamin D superimposed on the age-related
muscle dysfunction and onset of atrophy.
Effects of alfacalcidol and muscle fibre atrophy
The alfacalcidol-induced decrease in Gm muscle mass was
due to fibre type-specific atrophy and limited to type IIb
fibres in the low oxidative distal part of the muscle. It is
surprising, therefore, that the extensor digitorum longus
(EDL) and tibialis anterior (TA) muscles, primarily
Fig. 4 Serum levels of IL-6, adiponectin and leptin. IL-6 levels were
higher in old rats treated with alfacalcidol for 6 weeks (A6WO) and
vehicle (V6WO) than control adult rats (CA). Adiponectin levels of
the A6WO group were higher than those in the age-matched V6WO
group. Leptin levels of the A6WO group were lower than those in the
V6WO group. *different from CA at P B 0.05; ?different from
V6WO at P \ 0.05 (ANOVA, Bonferroni posthoc); data are repre-
sented as mean ± SEM
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consisting of type II fibres, did not show significant atrophy
[13]. This might be related to the different functions, where
the gastrocnemius and plantaris muscles, which atrophied,
are anti-gravity muscles and the EDL and TA are not. The
reduced activity and loading due to a loss of body mass
would result in a lesser recruitment of the type II fibres in
the low oxidative part of Gm and hence type II fibres in this
region would be most affected.
The selective type IIb fibre atrophy in our animals with
supra-physiological levels of vitamin D was unexpected
as vitamin D deficiency in older women was also
accompanied by selective type II fibre atrophy [44]. The
discrepancy may be related to the reduced food intake in
our alfacalcidol-treated animals [13], as in starved rodents
particularly the highly glycolytic (presumably IIb/x) fibres
have been reported to atrophy [45]. This, and the unal-
tered fibre type composition during starvation [45], as also
observed in our rats, suggest that any effect elevated
levels of 1,25D might have on fibre type composition and
fibre size is overruled by the effects of a reduced food
intake.
Alfacalcidol treatment-related decreased food intake
and muscle fibre atrophy
Leptin plays a key role in regulating energy intake and
energy expenditure where elevated leptin levels reduce
appetite. Yet, serum levels in alfacalcidol-treated rats were
decreased, rather than increased, and the decreased food
intake can thus not be explained by changes in leptin
levels.
Another factor that may play a role in the regulation of
body mass is adiponectin, an adipokine that is elevated
during weight loss [15], as was the case in our alfacalcidol-
treated animals. Since adiponectin enhances glucose uptake
and fatty acid oxidation in muscle [46] it might be a
response to minimize the use of muscle protein in the face
of starvation and ensure that probably elevated levels of
circulating fatty acids can be used for energy generation
[16].
Chronic low-grade systemic inflammation plays an
important role in the weight loss and muscle wasting
during ageing and chronic diseases, partly via reducing
appetite [42, 47, 48]. IL-6 is an inflammatory cytokine
and elevated circulating levels have been associated with
loss of muscle strength [18, 49] and atrophy [42, 47].
Treatment with alfacalcidol was, however, not accom-
panied with an increase in circulating IL-6 levels and
alfacalcidol has even been shown to decrease tumor
necrosis factor-a [50], another cytokine having a cata-
bolic effect on muscle [42]. It is thus unlikely that the
observed atrophy was the result of increased systemic
inflammation.
Effects of alfacalcidol and reduced food intake
on signalling pathways for protein synthesis
and degradation
We hypothesized that alfacalcidol treatment induces
hypertrophy since 1,25D has been shown to activate and
induce synthesis of c-myc [51, 52] as well as the MAP
kinases ERK1 and ERK 2 in skeletal muscle [53]. How-
ever, neither c-myc nor IGF-I Ea, myostatin nor a-skeletal
actin expression were changed by alfacalcidol treatment,
and we observed atrophy rather than hypertrophy.
It is possible that the intracellular concentration of
1,25D differs from that in the circulation due to the action
of CYP27B1, a hydroxylase that catalyses the hydroxyl-
ation of 25D to 1,25D. The potential importance of
CYP27B1 in muscle wasting has been shown by the muscle
atrophy in patients with chronic renal failure, which have
sufficient 25D but lack CYP27B1 [54] and thus may suffer
from intracellular vitamin D deficiency in the presence of
normal circulating 25D levels. These patients did indeed
improve muscle size and strength when they were treated
with 1,25D [55]. In our study, the CYP27B1 expression in
the muscle was not altered despite elevated serum levels of
1,25D (see Fig. 3d) after alfacalcidol treatment and this
may have also caused supraphysiological levels of 1,25D
within the cells.
Alternatively, the atrophy, rather than the expected
hypertrophy after alfacalcidol treatment, may be related to
the abundance and/or action of VDR. Yet, despite supra-
physiological 1,25D serum levels, the VDR mRNA
expression was not altered in the Gm of the alfacalcidol-
treated animals (see Fig. 3d). The atrophy of type II fibres
was therefore probably not due to a reduced abundance of
the VDR.
To our knowledge, there are no studies that have
addressed the impact of supraphysiological levels of vita-
min D on skeletal muscle. The hypercalcaemia, which we
observed previously in these same animals [13] and which
accompanies the elevated serum levels of 1,25D, has been
associated with muscle weakness and weight loss [56].
Nevertheless, it is likely that the 38% reduction in food
intake [13] is the main cause of the muscle wasting and loss
of body mass. It remains unclear, however, how elevated
levels of 1,25D cause this reduced food intake, but our data
indicate that it is not due to increased serum IL-6 and/or
altered circulating leptin levels, as discussed above.
During muscle atrophy, including that induced by fast-
ing [19–22], the expression of MuRF-1 and MAFbx have
been reported to be increased. MuRF-1 ubiquitinates
myofibrillar and cytoskeleton proteins and metabolic
enzymes in preparation for their subsequent breakdown
in the proteasome [57–60]. In line with this role in
muscle protein breakdown during fasting, we observed that
532 J Physiol Sci (2011) 61:525–535
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MuRF-1 expression was increased substantially in the alfa-
calcidol group, without a change in MAFbx mRNA levels
(see Fig. 3b). The latter is somewhat surprising as MAFbx is
also associated with accelerated muscle protein loss and its
mRNA increases 8–40-fold in many types of muscle atrophy
[61]. It should be noted, however, that MAFbx and MuRF-1
expression do not always change in a coordinated fashion
and their expression is controlled by different signalling
pathways [62]. Overall, the data indicate that the alfacalci-
dol-induced atrophy may at least partly be caused by an
increased mRNA expression of the E3 ligases.
Myostatin expression has been shown to be upregulated
in type II fibre atrophy [63]. Yet, despite the preferential
type II fibre atrophy in our study, no differences in myo-
statin expression in muscles from the alfacalcidol and
vehicle groups were found, suggesting that myostatin had
no role in the alfacalcidol-induced atrophy.
In conclusion, the observed decrease in muscle mass in
the presence of supraphysiological levels of the active form
of vitamin D, induced by alfacalcidol supplementation, is
due to preferential atrophy of type IIb. This atrophy was
associated with an increased mRNA expression of the
ubiquitin ligase MuRF-1 which was superimposed on the
age-related increase in MuRF-1 expression. The atrophy
and increased MuRF-1 expression were not due to increased
systemic inflammation, nor was it accompanied with
increased muscular myostatin or reduced IGF-1 Ea
expression. The data suggest that reduced food intake is the
main cause of the muscle atrophy and loss of body mass
when circulating levels of the active form of vitamin D are
supraphysiological. Occasionally, vitamin D intoxication is
also observed in the clinic [64]. However, the risk of vita-
min D intoxication may be exaggerated where the natural/
physiological regulation is overridden by supplementation
with VitD analogues, such as alfacalcidol, and is less when
treated with VitD3 or VitD2. Nevertheless, the clinical
implication is that care has to be taken that vitamin D
supplementation to vitamin D deficient patients does not
result in supraphysiological levels of circulating vitamin D,
and it extends the observation that vitamin D supplemen-
tation ‘‘does not have a significant effect on muscle strength
in adults with baseline 25(OH)D [ 25 nmol l-1’’ [65].
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